MPGDNLS cell-penetrating peptide
Sequence: GALFLGFLGAAGSTMGAWSQPKSKRKV
| Experiment Id | EXP002459 |
|---|---|
| Paper | Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) |
| Peptide | MPGDNLS cell-penetrating peptide |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | MPG stock 350 uM or CADY stock 370 uM; exact released peptide concentration not reported |
| Rna Concentration | siRNA stock 50 uM; scaffold-mediated delivery used siRNA/CPP volume ratio 1/4; bolus delivery used 20 nM siRNA for comparison |
| Mixing Ratio | siRNA/CPP volume ratio 1/4 for scaffold-mediated experiments; equivalent molar ratio ~1/30 for electrospinning; bolus optimization used 1/60 molar ratio |
| Formulation Format | electrospun PCLEEP nanofiber scaffold encapsulating siRNA/CPP complexes |
| Formulation Components | poly(caprolactone-co-ethyl ethylene phosphate) (PCLEEP) nanofibers; siCOL1A1 complexed non-covalently with CPP; scaffold-mediated sustained release |
| Size Nm | 636.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Female Sprague-Dawley rat subcutaneous implant model |
| Administration Route | subcutaneous implantation of aligned siCOL1A1/MPG PCLEEP nanofiber scaffold supported on PCL film |
| Output Type | fibrous capsule thickness after implantation |
| Output Value | siCOL1A1/MPG was tested in vivo, but the reported overall effect ranked MPG approximately similar to PCLEEP and below CADY/TKO; no clear significant reduction versus PCLEEP was reported. |
| Output Units | |
| Output Notes | Conservative negative: in vivo testing was performed, but functional in vivo delivery success was not clearly demonstrated for the MPG peptide scaffold. |
| Toxicity Notes | No acute or chronic inflammation or necrosis indicative of toxicity was identified for scaffolds at assessed time points. |
| Curation Notes |